2 Information about glecaprevir–pibrentasvir

2 Information about glecaprevir–pibrentasvir

Marketing authorisation

Glecaprevir–pibrentasvir (Maviret, AbbVie) has a marketing authorisation in the UK for the 'treatment of chronic hepatitis C virus infection in adults'. This includes genotypes 1–6, with or without compensated cirrhosis, in people with untreated disease or disease previously treated with interferon-based treatment or sofosbuvir plus ribavirin. It is not approved for people whose previous treatment included a NS3/4A and/or NS5A inhibitor.

Dosage in the marketing authorisation

The dosage is 300 mg/120 mg orally once daily. Treatment duration is 8, 12 or 16 weeks depending on genotype, cirrhosis status and whether the person has had previous treatment.

Price

The list price per pack is £12,993.66. The total costs are £25,987.32 for an 8-week course, £38,980.98 for 12 weeks and £51,974.64 for 16 weeks.

The company has agreed a nationally available price reduction for glecaprevir–pibrentasvir with the Commercial Medicines Unit. The contract prices agreed through the framework are commercial in confidence.

  • National Institute for Health and Care Excellence (NICE)